Tumor penetration of AMSA in man

Guo Zhengang; Niramol Savaraj; Lynn G. Feun; Katherine Lu; David J. Stewart; Mario Luna; Robert S. Benjamin; Ti Li Loo

doi:10.3109/07357908309020272

Tumor penetration of AMSA in man

Guo Zhengang, Niramol Savaraj, Lynn G. Feun, Katherine Lu, David J. Stewart, Mario Luna, Robert S. Benjamin, Ti Li Loo

Sarcoma Medical Oncology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

4)9-Acridinylamino)-methanesulfon-m-anisidide [AMSA) has shown significant antitumor activity against several murine tumors and leukemias. During its Phase I and II clinical trial, we were able to obtain tumors, plasma, and CSF specimens from patients who received varying doses of AMSA, as well as patients who received high doses and had autologous bone marrow rescue. The drug was analyzed chromatographically. The tumor to plasma drug concentration ratios ranged from 200% to 486% apparently independent of dose and sampling time. Because AMSA was not detected in the CSF, the drug may not be effective in the treatment of meningeal metastasis. High-dose AMSA therapy with bone marrow rescue did not result in significantly higher AMSA concentrations in the tumor, nor did it elicit favorable response.

Original language	English (US)
Pages (from-to)	475-478
Number of pages	4
Journal	Cancer Investigation
Volume	1
Issue number	6
DOIs	https://doi.org/10.3109/07357908309020272
State	Published - 1983

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3109/07357908309020272

Cite this

@article{d7e0ccf3a352471980eb4feee1701bd5,

title = "Tumor penetration of AMSA in man",

abstract = "4)9-Acridinylamino)-methanesulfon-m-anisidide [AMSA) has shown significant antitumor activity against several murine tumors and leukemias. During its Phase I and II clinical trial, we were able to obtain tumors, plasma, and CSF specimens from patients who received varying doses of AMSA, as well as patients who received high doses and had autologous bone marrow rescue. The drug was analyzed chromatographically. The tumor to plasma drug concentration ratios ranged from 200% to 486% apparently independent of dose and sampling time. Because AMSA was not detected in the CSF, the drug may not be effective in the treatment of meningeal metastasis. High-dose AMSA therapy with bone marrow rescue did not result in significantly higher AMSA concentrations in the tumor, nor did it elicit favorable response.",

author = "Guo Zhengang and Niramol Savaraj and Feun, {Lynn G.} and Katherine Lu and Stewart, {David J.} and Mario Luna and Benjamin, {Robert S.} and Loo, {Ti Li}",

note = "Funding Information: Supported in part by NCI Contract No. CM-87185 and Grant No. CA-14528.",

year = "1983",

doi = "10.3109/07357908309020272",

language = "English (US)",

volume = "1",

pages = "475--478",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "6",

}

TY - JOUR

T1 - Tumor penetration of AMSA in man

AU - Zhengang, Guo

AU - Savaraj, Niramol

AU - Feun, Lynn G.

AU - Lu, Katherine

AU - Stewart, David J.

AU - Luna, Mario

AU - Benjamin, Robert S.

AU - Loo, Ti Li

N1 - Funding Information: Supported in part by NCI Contract No. CM-87185 and Grant No. CA-14528.

PY - 1983

Y1 - 1983

N2 - 4)9-Acridinylamino)-methanesulfon-m-anisidide [AMSA) has shown significant antitumor activity against several murine tumors and leukemias. During its Phase I and II clinical trial, we were able to obtain tumors, plasma, and CSF specimens from patients who received varying doses of AMSA, as well as patients who received high doses and had autologous bone marrow rescue. The drug was analyzed chromatographically. The tumor to plasma drug concentration ratios ranged from 200% to 486% apparently independent of dose and sampling time. Because AMSA was not detected in the CSF, the drug may not be effective in the treatment of meningeal metastasis. High-dose AMSA therapy with bone marrow rescue did not result in significantly higher AMSA concentrations in the tumor, nor did it elicit favorable response.

AB - 4)9-Acridinylamino)-methanesulfon-m-anisidide [AMSA) has shown significant antitumor activity against several murine tumors and leukemias. During its Phase I and II clinical trial, we were able to obtain tumors, plasma, and CSF specimens from patients who received varying doses of AMSA, as well as patients who received high doses and had autologous bone marrow rescue. The drug was analyzed chromatographically. The tumor to plasma drug concentration ratios ranged from 200% to 486% apparently independent of dose and sampling time. Because AMSA was not detected in the CSF, the drug may not be effective in the treatment of meningeal metastasis. High-dose AMSA therapy with bone marrow rescue did not result in significantly higher AMSA concentrations in the tumor, nor did it elicit favorable response.

UR - http://www.scopus.com/inward/record.url?scp=0021044890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021044890&partnerID=8YFLogxK

U2 - 10.3109/07357908309020272

DO - 10.3109/07357908309020272

M3 - Article

C2 - 6689404

AN - SCOPUS:0021044890

SN - 0735-7907

VL - 1

SP - 475

EP - 478

JO - Cancer Investigation

JF - Cancer Investigation

IS - 6

ER -

Tumor penetration of AMSA in man

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this